Prof Ingrid Scheffer

Research

Professor Scheffer profiled in top-ranking journal

The story of Professor Ingrid Scheffer's early life and research career has been profiled in one of the world's most prestigious medical journals, The Lancet Neurology.

"To be profiled in such a journal is indication of the high regard with which Professor Scheffer is held by the international research community, and the impact that she has had in the field of neurology. We're extremely proud to see her achievements highlighted in such a way," says Austin Health chief medical officer, Dr. Fergus Kerr.

The Lancet Neurology has an impact factor of 26.284, making it the world's top ranked medical journal in clinical neurology.

Professor Scheffer, whose work has been supported by 20 years of continuous National Health and Medical Research Council (NHMRC) funding, is internationally-renowned for her role in the research group that uncovered the first gene for epilepsy - and later, several hundred other genes implicated in the disease. She also lead a major revision of the classification system for epilepsy, published last year, and was involved in pioneering research that showed that cannabidiol can reduce seizures in children with the rare epilepsy, Dravet syndrome.

"I wanted to do medicine because I wanted a career that combined intellectual curiosity and caring, and to make a difference", Prof. Scheffer told The Lancet Neurology. "And later, I found research especially rewarding, because it has far greater reach, with the potential to improve lives of people worldwide."


Read the full article in The Lancet Neurology.